Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and only tablet available for the treatment of spinal muscular atrophy (SMA), a rare, genetic neuromuscular condition. The label extension allows the 5mg tablet to be used across the EU, offering an alternative to the existing […]
The post Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy appeared first on Pharmafile.
